TREA

79200172 - GLYCOMAX

Follow

Information

  • Trademark
  • 79200172
  • Serial Number
    79200172
  • Registration Number
    5515976
  • Filing Date
    August 24, 2016
    8 years ago
  • Registration Date
    July 17, 2018
    6 years ago
  • Transaction Date
    July 17, 2023
    a year ago
  • Status Date
    July 17, 2018
    6 years ago
  • Published for Opposition Date
    January 30, 2018
    6 years ago
  • Location Date
    July 17, 2018
    6 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    NADELMAN, ANDREA KOYNE
  • Attorney Docket Number
    4941-033TM
    Attorney Name
    Jeffrey H. Greger
    Law Office Assigned Location Code
    M10
  • Owners
Information
Mark Drawing Code
5000
Mark Identification
GLYCOMAX
Case File Statements
  • GS0291: Dairy produce and dairy products, namely, dairy-based beverages, dairy-based powders for making dairy-based food beverages and shake and dairy-based spreads; milk products excluding ice cream, ice milk and frozen yoghurt; milk; milk powder other than for babies; milk protein and milk protein products; milk powder replacers in the nature of milk powder; preparations for making milk based beverages in the nature of powdered milk; prepared meals consisting primarily of meat, fruit or vegetables
  • GS0051: Pharmaceutical preparations and substances, namely, skincare preparations and substances; pharmaceutical preparations derived from dairy sources for skin care and the treatment of eczema, psoriasis and other skin conditions; pharmaceutical preparations for the therapeutic treatment of diabetes; pharmaceutical preparations for skin care and pharmaceutical preparations for application to the skin for skin care, the treatment of eczema, psoriasis and other skin conditions; pharmaceutical preparations for the treatment of dermatitis; pharmaceutical preparations for boosting the immune system; pharmaceutical preparations and products for treatment of metabolic disorders; pharmaceutical preparations and substances whose primary purpose is to boost metabolism or fat burning; pharmaceutical agents for activating metabolism; dietary medical preparations for slimming purposes, including food supplements; dietary nutritional supplements not for medical purposes; dietetic substances, namely, dietetic foods adapted for medical use, including dietetic substances for use in weight control; dietetic foodstuffs for medical use in the form of prepared meals, namely, dietetic foods adapted for medical use; dietetic beverages adapted for medical purposes; dietetic additives for food, namely, meal replacements in the nature of powdered nutrition and protein supplements; meal supplements in the nature of dietary supplements and other formulated powdered preparations in the nature of glucose for use as an additive to foods for medical purposes; protein for dietetic purposes, namely, protein supplements; energy drinks in the nature of dietary supplemental drinks and energy drinks that are adapted for medical purposes, namely, dietary supplemental drinks; medicated preparations for use as additives for food for human consumption, namely, vitamin preparations for use as a supplement for dietary supplements and infant formula; foods for persons having complex metabolic disorders, namely, meal replacements in the nature of meal replacement bars adapted for medical use, meal supplements in the nature of nutritional supplement meal replacement bars for boosting energy, and other formulated powdered preparations, namely, powdered dietary supplements; foodstuffs for use in the dietary management of obesity, namely, special dietary foods, beverages and meal replacements in the nature of dietetic foods, namely, pasta adapted for medical use, meal replacement bars for weight loss purposes and meal replacement beverages adapted for medical use; health food supplements for persons with special dietary requirements; dried milk products for babies, namely, dried milk powder for babies; milk foods for babies; human milk oligosaccharide dietary supplements; human milk oligosaccharide compounds, namely, milk sugar for medical purposes; human milk oligosaccharide additives for use as nutritional supplements in connection with pharmaceuticals and infant formula; human milk oligosaccharide additives for use as a dietary or nutritional supplement; human milk oligosaccharide compounds, namely, milk sugar for medical use; health food supplements and mineral supplements, namely, mineral supplements for foodstuffs for human consumption; medicated mineral drinks, namely, medicated mineral spring waters; nutritional supplements, namely, nutritional supplements containing nut and fish oils; nutritional meal replacement powders in the nature of meal replacement powdered drink mixes adapted for medical use; nutritional meal replacements, namely, nutritional meal replacement bars, milkshakes and other powdered preparations adapted for medical use for individuals preparing for or undergoing medical treatments; non-carbohydrate dietary supplements other than for medical use; powdered dietary food concentrates in the nature of dietary supplement drink mixes; powdered dietary food concentrates in the nature of weight management supplements for use in weight reduction programmes for medical purposes; preparations for use as additives to food for consumption, namely, minerals and vitamin supplements; protein preparations in the nature of protein supplements for use as additives to foodstuffs for human consumption; protein based food preparations, being dietetic protein supplements and nutritional additives that are not for medical purposes in the nature of protein dietary supplements; slimming aids for medical use, namely, weight management products in the nature of dietary nutritional supplements; slimming preparations for medical use, namely, meal replacement shakes for weight loss purposes; slimming products for medical use, namely, stimulatory medications for use in weight reduction programmes; vitamins and vitamin supplements; none of the foregoing goods including cell lines, antibodies or proteins for pharmaceutical use
  • CC0000: Color is not claimed as a feature of the mark.
Case File Event Statements
  • 7/17/2023 - a year ago
    43 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3
  • 11/16/2018 - 6 years ago
    42 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 10/30/2018 - 6 years ago
    41 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 10/30/2018 - 6 years ago
    40 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 10/17/2018 - 6 years ago
    39 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 7/17/2018 - 6 years ago
    38 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 6/29/2018 - 6 years ago
    37 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 6/14/2018 - 6 years ago
    36 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 6/14/2018 - 6 years ago
    35 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 6/10/2018 - 6 years ago
    34 - EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Type: ETOP
  • 5/16/2018 - 6 years ago
    33 - CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED Type: CHPB
  • 5/15/2018 - 6 years ago
    32 - ASSIGNED TO PETITION STAFF Type: APET
  • 4/27/2018 - 6 years ago
    31 - TEAS POST PUBLICATION AMENDMENT RECEIVED Type: EPPA
  • 2/22/2018 - 6 years ago
    30 - EXTENSION OF TIME TO OPPOSE RECEIVED Type: ETOF
  • 1/30/2018 - 6 years ago
    29 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 1/30/2018 - 6 years ago
    28 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 1/26/2018 - 7 years ago
    27 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 1/10/2018 - 7 years ago
    26 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 1/10/2018 - 7 years ago
    25 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 1/10/2018 - 7 years ago
    24 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 12/18/2017 - 7 years ago
    23 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 12/18/2017 - 7 years ago
    22 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 12/18/2017 - 7 years ago
    21 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 12/18/2017 - 7 years ago
    20 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 12/18/2017 - 7 years ago
    19 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 12/7/2017 - 7 years ago
    18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/7/2017 - 7 years ago
    17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/7/2017 - 7 years ago
    16 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 6/20/2017 - 7 years ago
    15 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 6/20/2017 - 7 years ago
    14 - FINAL REFUSAL E-MAILED Type: GNFR
  • 6/20/2017 - 7 years ago
    13 - FINAL REFUSAL WRITTEN Type: CNFR
  • 5/31/2017 - 7 years ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 5/31/2017 - 7 years ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 5/31/2017 - 7 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/18/2017 - 7 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 1/25/2017 - 8 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 1/25/2017 - 8 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 1/20/2017 - 8 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 1/19/2017 - 8 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 1/17/2017 - 8 years ago
    4 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 1/13/2017 - 8 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 1/13/2017 - 8 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 1/12/2017 - 8 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR